专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019089848A1 METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY 审中-公开
公开(公告)号：WO2019089848A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/058579
申请日：2018-10-31
申请人： JUNO THERAPEUTICS, INC.
发明人： ALBERTSON, Tina , GARCIA, Jacob Randolph , LI, He
IPC分类号： G01N33/50 , A61K35/17 , G01N33/574
CPC分类号： G01N33/5014 , A61K35/17 , G01N33/57426 , G01N2800/52 , G01N2800/56
摘要： Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.

2. 发明申请

WO2020113194A2 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY 审中-公开
公开(公告)号：WO2020113194A2
公开(公告)日：2020-06-04
申请号：PCT/US2019/063889
申请日：2019-11-29
申请人： JUNO THERAPEUTICS, INC.
发明人： ALBERTSON, Tina , GARCIA, Jacob Randolph , GILBERT, Mark , LI, He , SUTHERLAND, Claire
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00
摘要： Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.

3. 发明申请

WO2019109053A1 METHODS FOR DOSING AND FOR MODULATION OF GENETICALLY ENGINEERED CELLS 审中-公开
公开(公告)号：WO2019109053A1
公开(公告)日：2019-06-06
申请号：PCT/US2018/063502
申请日：2018-11-30
申请人： JUNO THERAPEUTICS, INC.
发明人： ALBERTSON, Tina , HEIPEL, Mark D. , LI, He , SUTHERLAND, Claire L.
IPC分类号： A61K31/573 , C07K16/28 , A61P43/00 , G01N33/68
CPC分类号： A61K31/573 , A61K39/001112 , A61K39/39541 , A61K39/39558 , A61K48/0083 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/545 , A61K2039/55 , A61K2039/804 , A61P35/02 , A61P43/00 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K16/2803 , C07K16/2866 , C07K2317/622 , C07K2319/03 , C07K2319/33 , C07K2319/40 , G01N33/6866 , G01N2333/7155 , A61K2300/00
摘要： Provided are methods of treatment, such as methods involving administering and/or determining dosing of, cell therapy, such as of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range and/or window for dosing, for example, based on the estimated probabilities of risk of developing a toxicity and estimated probabilities of a treatment outcome or response, such as treatment, reduction nor amelioration of a sign or symptom thereof, or degree or durability thereof, following administration of the cell therapy or engineered cells. In some aspects, the methods involve administering an agent capable of modulating the engineered cells. Also provided are methods of ameliorating and/or treating a toxicity.

4. 发明申请

WO2018157171A3 COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS RELATED TO DOSING IN CELL THERAPY 审中-公开
公开(公告)号：WO2018157171A3
公开(公告)日：2018-08-30
申请号：PCT/US2018/020054
申请日：2018-02-27
申请人： JUNO THERAPEUTICS, INC.
发明人： CHRISTIN, Brian , COVINGTON, Michael, Gerard , DAVE, Kedar, Himanshu , GETTO, Richard, James, Jr. , KOWSKI, Tom , LARSON, Ryan, P. , RAMSBORG, Christopher, Glen , TREDE, Nikolaus, Sebastian , WEBER, Clinton , WHITMORE, James, Boyd , YEE, Nathan , BEAUCHESNE, Pascal , BECKETT, Travis , BLACKMAN, Samuel, Charles , CHARTRAND, Nathaniel , DAVIS-PICKETT, Mel , GILBERT, Mark , LAMBERT, Nathaniel , LI, He , MALLANEY, Mary , POLLOCK, Kathryn, Lindsay , ODEGARD, Valerie , SMITH, Jeff , SUTHERLAND, Claire , WALKER, Andrew, W.
IPC分类号： A61K35/17
摘要： Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

5. 发明申请

WO2018102787A9 METHODS FOR DETERMINING CAR-T CELLS DOSING 审中-公开
公开(公告)号：WO2018102787A9
公开(公告)日：2018-06-07
申请号：PCT/US2017/064364
申请日：2017-12-01
申请人： JUNO THERAPEUTICS, INC.
发明人： LI, He , ALBERTSON, Tina , HEIPEL, Mark, D. , SUTHERLAND, Claire, L.
IPC分类号： A61K39/395 , A61K39/44 , A61K39/00
摘要： Provided are methods of determining dosing of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range for dosing by the estimated probabilities of risk of developing a toxicity and estimated probabilities of response to the engineered cells when administered.

6. 发明申请

WO2018102787A1 METHODS FOR DETERMINING CAR-T CELLS DOSING 审中-公开
公开(公告)号：WO2018102787A1
公开(公告)日：2018-06-07
申请号：PCT/US2017/064364
申请日：2017-12-01
申请人： JUNO THERAPEUTICS, INC.
发明人： LI, He , ALBERTSON, Tina , HEIPEL, Mark, D. , SUTHERLAND, Claire, L.
IPC分类号： A61K39/395 , A61K39/44 , A61K39/00
摘要： Provided are methods of determining dosing of cells engineered with a recombinant receptor, such as a T cell receptor (TCR) or chimeric antigen receptor (CAR). In some embodiments, the methods include determining a therapeutic range for dosing by the estimated probabilities of risk of developing a toxicity and estimated probabilities of response to the engineered cells when administered.

7. 发明申请

WO2017161212A1 METHODS FOR ADAPTIVE DESIGN OF A TREATMENT REGIMEN AND RELATED TREATMENTS 审中-公开
标题翻译：治疗方案和相关治疗的自适应设计方法
公开(公告)号：WO2017161212A1
公开(公告)日：2017-09-21
申请号：PCT/US2017/022849
申请日：2017-03-16
申请人： JUNO THERAPEUTICS, INC. , CONNOR, Jason , QUINTANA, Melanie
发明人： CONNOR, Jason , QUINTANA, Melanie , LI, He , ALBERTSON, Tina
IPC分类号： G06F19/00
摘要： Provided herein are methods for adaptive design of a treatment regimen for treatment of subjects with a therapeutic agent. In some embodiments, the methods can determine the optimal dosing regimen, such as dose level and/or schedule to administer to a subject. In some embodiments, the methods can be used for determining dosing regimens in clinical trials, such as Phase I clinical trials. In some embodiments, one or more of or all of the steps of the method occur at an electronic device containing one or more processors and memory, such as implemented by a computer. Also provided are methods of administering a therapeutic agent to a subject in accord with an adaptive dosing regimen designed to identify an optimal dose and/or schedule of a therapeutic agent for treating a disease or condition.
摘要翻译：本文提供用于自适应设计用于用治疗剂治疗受试者的治疗方案的方法。在一些实施方案中，所述方法可以确定最佳给药方案，例如给予对象的剂量水平和/或时间表。在一些实施方案中，该方法可用于确定临床试验中的给药方案，例如I期临床试验。在一些实施例中，该方法的一个或多个或全部步骤发生在包含一个或多个处理器和存储器的电子设备处，例如由计算机实现的。还提供了根据设计用于鉴定用于治疗疾病或病症的治疗剂的最佳剂量和/或时间表的适应性给药方案向对象施用治疗剂的方法。

8. 发明申请

WO2017161208A1 METHODS FOR DETERMINING DOSING OF A THERAPEUTIC AGENT AND RELATED TREATMENTS 审中-公开
标题翻译：确定治疗剂剂量和相关治疗的方法
公开(公告)号：WO2017161208A1
公开(公告)日：2017-09-21
申请号：PCT/US2017/022844
申请日：2017-03-16
申请人： JUNO THERAPEUTICS, INC. , JI, Yuan
发明人： JI, Yuan , LI, He
IPC分类号： G06F19/00
摘要： Provided herein are methods employing a toxicity and efficacy probability interval (TEPI) design for performing a clinical trial, such as a Phase I dose-finding trial. In some embodiments, the methods can be used in the dosing of subjects administered a therapy, such as adoptive cell therapy or other immunotherapy, where safety and efficacy data for a therapeutic agent can be observed in the same timeframe or period. In some embodiments, one or more of or all of the steps of the method occur at an electronic device containing one or more processors and memory, such as implemented by a computer. Also provided are methods of administering a therapeutic agent to a subject in accord with the dosing decisions.
摘要翻译：本文提供了采用毒性和效力概率区间（TEPI）设计进行临床试验（例如I期剂量发现试验）的方法。在一些实施方案中，所述方法可以用于施用治疗的受试者的剂量，例如过继性细胞疗法或其他免疫疗法，其中治疗剂的安全性和有效性数据可以在相同的时间范围或时间段内观察到。在一些实施例中，该方法的一个或多个或全部步骤发生在包含一个或多个处理器和存储器的电子设备处，例如由计算机实现的。还提供了根据给药决定向受试者施用治疗剂的方法。

9. 发明申请

WO2017096331A1 METHODS AND COMPOSITIONS RELATED TO TOXICITY ASSOCIATED WITH CELL THERAPY 审中-公开
标题翻译：与细胞疗法有关的毒性的方法和组合物
公开(公告)号：WO2017096331A1
公开(公告)日：2017-06-08
申请号：PCT/US2016/064865
申请日：2016-12-02
申请人： JUNO THERAPEUTICS, INC. , FRED HUTCHINSON CANCER RESEARCH CENTER
发明人： LI, He , GILBERT, Mark J. , MALONEY, David , RIDDELL, Stanley R. , TURTLE, Cameron J.
IPC分类号： G01N33/68
CPC分类号： G01N33/6863 , A61K39/0011 , A61K2039/5156 , A61K2039/5158 , G01N33/6866 , G01N33/6869
摘要： Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods further involve administering an agent or therapy for treating, ameliorating, preventing, delaying and/or attenuating the development of the toxicity, such as neurotoxicity or CRS, such as severe neurotoxicity or severe CRS.
摘要翻译：提供了涉及与施用细胞疗法以治疗疾病或病症（例如癌症）有关的毒性的方法，试剂盒和组合物，包括用于预测和治疗毒性的方法。在一些实施方案中，毒性是神经毒性或细胞因子释放综合征（CRS），例如严重的神经毒性或严重的CRS。该方法通常包括检测生物标志物的参数或单独检测生物标志物组（例如浓度，量或活性）中的每个生物标志物的参数，并将检测到的参数与参数的参考值比较以确定受试者是处于产生毒性的风险中，例如神经毒性或CRS或严重神经毒性或严重CRS。在一些实施方案中，所述方法还包括施用用于治疗，改善，预防，延迟和/或减轻毒性发展的药剂或疗法，所述毒性例如神经毒性或CRS，例如严重的神经毒性或严重的CRS。

10. 发明申请

WO2020113194A3 METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY 审中-公开
公开(公告)号：WO2020113194A3
公开(公告)日：2020-06-04
申请号：PCT/US2019/063889
申请日：2019-11-29
申请人： JUNO THERAPEUTICS, INC.
发明人： ALBERTSON, Tina , GARCIA, Jacob Randolph , GILBERT, Mark , LI, He , SUTHERLAND, Claire
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00
摘要： Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式